Overview

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Status:
Unknown status
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
Evaluation of the safety and efficacy of CAR19 T cells carrying cytoplasmic activated PD1 in patients with refractory relapsed B-cell lymphoma
Phase:
Phase 1
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborator:
The Pregene (ShenZhen) Biotechnology Company, Ltd.